AKRO

Akero Therapeutics
AKRO

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$3.43B
EV
$2.67B
Shares Outstanding
82.90M
Beta
-0.18

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$77.64
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Akero Therapeutics, Inc.

gainify
AKRO

Akero Therapeutics, Inc.

AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that pro...

Sector

Healthcare

Industry

Biotechnology

CEO

Cheng, Andrew

Employees

63

IPO Date

2019-06-20

Headquarters

601 Gateway Boulevard, Suite 350, South San Francisco, California, 94080, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved